All News OLIPASS Corporation

Equities

A244460

KR7244460002

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
519 ^KRW	-2.81%		-0.57%	-32.95%

Mar. 18	OLIPASS Corporation announced that it has received KRW 3.5 billion in funding	CI
Mar. 06	OLIPASS Corporation announced that it expects to receive KRW 5 billion in funding	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

OLIPASS Corporation announced that it has received KRW 3.5 billion in funding	Mar. 17	CI
OLIPASS Corporation announced that it expects to receive KRW 5 billion in funding	Mar. 05	CI
OLIPASS Corporation announced that it expects to receive KRW 12.50000032 billion in funding	Dec. 17	CI
OliPass Corporation Discloses Painful But Hilarious Clinical Findings from a Phase 2a Trial in OA Patients with Nav1.7 Selective Inhibitor OLP-1002	Nov. 13	CI
OLIPASS Corporation announced that it has received KRW 4.99998978 billion in funding	23-09-17	CI
OLIPASS Corporation announced that it expects to receive KRW 4.999998885 billion in funding	23-09-03	CI
OLIPASS Corporation announced that it expects to receive KRW 4.99998978 billion in funding	23-09-03	CI
OLIPASS Corporation(KOSDAQ:A244460) dropped from S&P Global BMI Index	23-08-24	CI
OLIPASS Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20	CI
OliPass Corporation Announces Nav1.7 Selective Inhibitor OLP-1002 Shows Strong Efficacy and Long Therapeutic Duration According to Interim Findings from Phase 2A Study in OA Patients	23-03-16	CI
OLIPASS Corporation announced that it expects to receive KRW 2.999989475 billion in funding from BNB Asset Co., Ltd.	22-12-12	CI
Vanda Pharmaceuticals Inc. and OliPass Announce Strategic Partnership to Develop Antisense Oligonucleotide Therapeutics	22-09-29	CI
OliPass Corporation Moves Forward to Second Stage of Phase 2a Trial for Pain Killer OLP-1002	22-07-18	CI
OliPass Corporation Announces Commencement of Dosing in Phase 2a Trial for Pain Killer OLP-1002	22-02-18	CI
OLIPASS Corporation Announces SCN9A Antisense Pain Killer OLP-1002 Moves into Phase 2a Stage	21-10-25	CI
OLIPASS Corporation announced that it has received KRW 35.4996288 billion in funding from a group of investors	20-11-29	CI
OLIPASS Corporation announced that it expects to receive KRW 35.4996288 billion in funding from a group of investors	20-11-17	CI
OLIPASS Corporation(KOSDAQ:A244460) added to S&P Global BMI Index	20-09-21	CI
OLIPASS Corporation announced that it has received KRW 14 billion in funding from KB Securities Co.,Ltd, Daishin Securities Co., Ltd., Mirae Asset Daewoo Co., Ltd., NH Investment & Securities Co., Ltd.	19-12-19	CI
OLIPASS Corporation announced that it expects to receive KRW 14 billion in funding from KB Securities Co.,Ltd, Daishin Securities Co., Ltd., Mirae Asset Daewoo Co., Ltd., NH Investment & Securities Co., Ltd.	19-12-17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News OLIPASS Corporation

Equities

A244460

KR7244460002

All News

Filters